1. National Immunoglobulin Database Meeting Procurement Update
9th December DH – Leading the nation’s health and care
Commercial Medicines Unit

2. Role of CMU
Deliver efficiencies for the NHS and DH in the procurement of medicines
Initiate procurement and support the DH purchasing for safety  agenda of those medicines
Ensure an efficient and effective supply chain of medicines to the patient
Analysis and interpretation of data (Pharmex)
Homecare, Branded, Generics, Specialised, Vaccines / Emergency Planning
Products & Services list
Move to NHS England
DH – Leading the nation’s health and care Commercial Medicines Unit

3. Current Framework update
1 June 2013 to 31 May 2015 (extended to 28 Feb 2017)
Further extension by 3 months
Framework covering England and N Ireland
£162 million per annum expenditure
5.4 million grams of Immunoglobulin p.a.
Price per gram paid reduced 6.84% 2011 to 2016
Management / communication of supply issues
One brand represent 55% of IVIG market share
Business case for next framework
Separate framework tendered for albumin & anti-D IG
DH – Leading the nation’s health and care

4. Summary of Annual Immunoglobulin Sales 2011 – 2016 (England and N Ireland)
Grams
Usage:
To show simple data relationships in various categories
How-to:
Right click on the graph to edit the data (adding categories, additional bars etc)
Always make sure that both axis are appropriately labelled, with units
Add data labels where possible/appropriate (remove them if the slide becomes too busy/unreadable)
Use consistent, complimentary colours in the graph
Ensure there is an accurate legend
Add footnotes if required, delete the notes box if not required

5. Previous tender No guaranteed volumes
Requested volumes based on scoring assessment
51% price
15% product volumes
15% quality (packaging, shelf-life, infusion times, bar-coding)
13% contingency
6% service
DH – Leading the nation’s health and care

6. Next tender considerations:
Incorporating volume bands?
Management of market share?
How this would work alongside Clinical Guidelines for use – existing LT patients, new LT patients, ST treatments
New products now in market and/or on horizon – do we want all on the framework?
Additional considerations regarding Homecare use?
Increasing use of 10% IVIG product
Impacts of Brexit / DH Statutory Scheme changes
Overhaul weightings and scoring accordingly
DH – Leading the nation’s health and care

7. Stakeholder input Any comments or considerations for tender strategy
Direct or indirect input into the tender process
Does the forecasting process work?
Representation from clinical, nursing, homecare, commissioning, patient group and pharmacy
Ongoing engagement with industry prior to tender issue
Stakeholder engagement – December / January
Tender issue February
Evaluation and award March/April
Start 1 June 2017
DH – Leading the nation’s health and care

8. Contact Details
If any queries regarding framework or interest in being involved in the next tender process: David Ford Tel
DH – Leading the nation’s health and care